UnitedHealth Stock Falls as Lawmakers Eye Insurers, PBMs
UnitedHealth stock is continuing to fall Thursday after the introduction of bipartisan legislation targeting PBMs and healthcare giants. Here's what to know.


UnitedHealth Group (UNH) stock is continuing its drawdown Thursday after lawmakers introduced a bipartisan bill aimed at prohibiting the joint ownership of pharmacy benefit managers (PBMs) and pharmacies.
The bill, the Patients Before Monopolies (PBM) Act, was introduced by Senators Elizabeth Warren, D-Mass., and Josh Hawley, R-Mo., and Representatives Diana Harshbarger, R-Tenn., and Jake Auchincloss, D-Mass. The act would prohibit the parent company of a PBM or an insurer from owning a pharmacy business and would require that the business in violation of the bill, if passed, would have to divest its pharmacy business within three years.
"Over the past decade, pharmacy benefit managers – the middlemen between pharmacies and insurance companies – have morphed into large healthcare conglomerates that exercise control over every link in the prescription drug delivery chain," the lawmakers said in a joint press release.

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"Today, the largest healthcare conglomerates each own a PBM – which pay for pharmacy services – as well as the pharmacy chains that provide those services. This inherent conflict of interest results in higher drug costs for patients and fewer independent pharmacies, but bigger profits for the corporate healthcare giants," the add.
UnitedHealth's PBM, Optum Rx, is the second-largest pharmacy benefits manager in the United States with a 20.8% market share. This falls just behind CVS Health's (CVS) Caremark unit with a 21.3% market share, according to Fierce Healthcare.
"We would expect passage of this proposed bill as uncertain, and would likely be part of a broader PBM reform which might also be linked to a drug pricing bill," says Bernstein analyst Lance Wilkes. "We would expect this type of legislation to more likely be evaluated in the next two years, and would see PBM reforms such as prohibiting retail spread and retained rebates in favor of administrative fees, as likely to be included in this type of reform."
Is UnitedHealth stock a buy, sell or hold?
UnitedHealth shares were up more than 18% on a total return basis (price change plus dividends) for the year to date in mid-November, but have nearly erased this gain following the fatal shooting of the CEO of its insurance unit. Indeed, the healthcare stock is clinging to a 2.9% lead at last check.
Still, Wall Street remains bullish on Dow Jones stock. According to S&P Global Market Intelligence, the average analyst target price for UNH stock is $636.20, representing implied upside of about 20% to current levels. Additionally, the consensus recommendation is Strong Buy.
Financial services firm Argus Research is one of those with a Buy rating on UNH and recently raised its price target on the large-cap stock to $670 from $600.
"Despite an outlook for 2025 from Buy-rated UnitedHealth Group that fell short of the Street’s expectations, we believe the long-term growth engines for UnitedHealth remain intact," wrote Argus Research analyst David Toung in a December 4 note. "Management acknowledges that the outlook is conservative, leaving room for outperformance, in our view. The company has numerous levers to pull to improve operating margins over the next 12 months."
Related content
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Joey Solitro is a freelance financial journalist at Kiplinger with more than a decade of experience. A longtime equity analyst, Joey has covered a range of industries for media outlets including The Motley Fool, Seeking Alpha, Market Realist, and TipRanks. Joey holds a bachelor's degree in business administration.
-
Trump's Immigration Policies and the Price of Home Healthcare: First 100 Days
President Trump's immigration policies may wallop your pocketbook if you rely on a home healthcare aide.
-
Stock Market Today: Stocks Extend a Quiet Winning Streak
The S&P 500 Index could actually close April with a monthly gain, which would be an extraordinary sign of market resilience.
-
Stock Market Today: Dow Drops 971 Points as Powell Pressure Ramps Up
President Trump is increasing his attacks against Jerome Powell, insisting the Fed chair cut interest rates.
-
Stock Market Today: No 'Powell Put'? No Problem
Investors, traders and speculators look beyond both another Trump post and more signs of slowing economic activity.
-
Which Stocks Stayed Green as the Market Plummeted?
Only a handful of S&P 500 stocks managed to generate gains during the market's historic four-day plunge.
-
Stock Market Today: Tariff Talks Drive Another Up-and-Down Day
Trade war negotiations are happening, but the "fear gauge" is gyrating, and investors, traders and speculators are still searching for signs of a bottom.
-
M&A Is Why UnitedHealth Group Stock Is in of the 100,000% Return Club
UnitedHealth has given a master class in mergers and acquisitions over the years.
-
UnitedHealth Stock Drags on the Dow After DOJ Probe News
UnitedHealth Group stock is sinking Friday on reports the Justice Department is investigating the health insurer. Here's what to know.
-
Stock Market Today: Markets Tumble on DeepSeek Shock
A cheap AI chatbot from China disrupted the biggest U.S. tech companies.
-
Stock Market Today: Stocks Pause After a Big Rally
The Nasdaq continues to lag the S&P 500 and the Dow so far in 2025.